Identification of LIG1 and LIG3 as prognostic biomarkers in breast cancer

Abstract

DNA ligase (LIG) plays a key role in connecting the 3′-OH end of a DNA strand to the 5′-P end of another DNA strand, resulting in the formation of a phosphodiester bond. It has been reported that LIGs (including LIG1, LIG3 and LIG4) play important roles in the occurrence and progression of many cancers. However, the role of LIGs in breast cancer (BC) is still unclear. In this study, we aim to reveal the expression level, function, and prognostic value of LIGs in BC. Bioinformatic tools were used to study the expression level, potential function and prognostic value of LIG1 and LIG3 in BC patients. ENCORI was used to predict microRNAs (miRNAs) that regulate LIG1 and LIG3 and established a valuable miRNA–mRNA regulation network for BC. We found that the expression of LIG1 and LIG3 was upregulated in BC and predicted high relapse-free survival (RFS) in BC patients. Functional annotation analysis was performed to reveal the role of LIG1 and LIG3 in BC. In addition, hsa-miR-22-3p was identified to be potentially involved in the regulation of LIG3. We suggest that LIG1 and LIG3 are novel valuable prognostic biomarkers for BC and has-miRNA-22-3p may be a potential therapeutic target for BC.

Desenvolvimento e validação de um score de desregulação das vias de reparo de DNA na predição do prognóstico em diferentes tipos de câncer

“…O gene PDSB5 compõe dois scores de desregulação que têm a capacidade de prever a sobrevivência de pacientes em 14 das coortes, incluindo a BRCA. Outro exemplo de genes envolvidos no prognóstico do câncer é o LIG3, sendo um biomarcador de prognóstico em câncer de mama (Sun et al, 2021), e sua superexpressão relacionada a fenótipos agressivos, resistência à platina e baixa sobrevida livre de progressão em câncer de mama (Ali et al, 2021). Embora apenas componha um score de desregulação com valor preditivo nas coortes BLCA e BRCA, este gene está sabidamente alterado em múltiplos tumores, como câncer de mama, leucemias, neuroblastoma e outros (Tomkinson et al, 2020).…”